Barclays PLC grew its stake in biote Corp. (NASDAQ:BTMD – Free Report) by 52.3% in the third quarter, Holdings Channel.com ...

As previously reported, Craig-Hallum initiated coverage of Biote (BTMD) with a Buy rating and $12 price target Consumer interest in next-gen therapies like hormone replacement therapy, or HRT ...

He is the founder of the Institute for Hormonal Balance, a clinic specializing in hormone replacement therapies, and BioTE Medical, the largest provider of hormone implants in the United States and a ...

and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. Receive News & Ratings for biote Daily - Enter your email address ...